FDA grants priority review to infigratinib for cholangiocarcinoma

The FDA granted priority review designation to infigratinib for the treatment of cholangiocarcinoma, according to the agent’s manufacturer.The agency will review the application under its Real-Time Oncology Review pilot program, designed to accelerate the delivery of effective and safe cancer treatments to patients.Infigratinib (BridgeBio Pharma/QED Therapeutics) is an oral FGFR1-3 selective inhibitor in development for people with FGFR-driven conditions, including cholangiocarcinoma, urothelial carcinoma and achondroplasia.Approximately 20,000 people in the United States are diagnosedRead More

Share on facebook
Share on twitter
Share on linkedin